FolioLanternBeta
BSXBoston Scientific · Insider ownership research

Boston Scientific insiders sold $24.3M in the past 12 months. How much of their stake is that?

About 8.1% of the shares they held or received (after tax withholding) during the period. The usual measure, against starting holdings alone, can't be used here because most of the shares sold arrived during the period, through vesting or option exercises.

Updated Oct 9, 2026 from SEC filings · covers Oct 10, 2025 to Oct 9, 2026
How this comparesMore of their stake sold than at 342 of the 539 other companies we can measure (#198 of 540)See ranking
5
buyers among officers and directors (10 trades), past 12 months
100%
of sales were under disclosed trading plans, past 12 months
4 of 20
officers and directors sold shares, past 12 months
Recent activity · past 30 days, Sep 10, 2026 to Oct 9, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 2, 2026Padraig O'Connor had 567 shares ($27K) withheld by the company for taxes (not a market sale). That is 6.9% of the total stake held that day. 1.2K shares came in from vesting or option exercises the same day, so the holding rose by 604 net.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Padraig O'Connor
EVP, Global Operations
567$48.376.9%7.6KSep 2, 2026Sep 3, 2026

"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Is this normal? Less than usual: about one-fifth of the 5-year average. 4 insiders sold; the average is 12 a year. Year by year
Latest filing: Filed Sep 3 for a tax withholding on Sep 2. Padraig O'Connor had 567 shares withheld by the company for taxes. Filing
59 SEC ownership filings in the period · See the evidence

What stands out

Five insiders bought shares: Michael Mahoney (186K shares, $9.0M), Edward Ludwig (8.6K shares, $430K) and David Habiger (7.7K shares, $408K), plus 2 more.Michael Mahoney: purchase, Aug 3, 2026 · Edward Ludwig: purchase, Jul 31, 2026 · David Habiger: purchase, May 20, 2026
Ellen Zane sold 70% of vested holdings: 26K shares for $2.6M, all under a disclosed plan.Largest sale, Nov 6, 2025

Percentages cover 17 of 20 officers and directors. Left out: Emily Woodworth (holdings couldn't be fully reconciled); Cheryl Pegus and Christophe Weber (held no vested shares at the start). Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.

SoldRest of starting stake
Michael Mahoney
Chairman, President & CEO, Director
Sold $15.0M (plan status beside the amount). Exercised options and sold: 7% of the shares held or received (after tax withholding) during the period†. Stake: 1.68M → 1.61M. Why
$15.0MDisclosed plan
Joseph Fitzgerald
EVP & Group Pres, Cardiology
Sold $5.0M (plan status beside the amount). Exercised options and sold: 15% of the shares held or received (after tax withholding) during the period†. Stake: 184K → 283K. Why
$5.0MDisclosed plan
Ellen Zane
Director
70% · $2.6MDisclosed plan
Arthur Butcher
EVP& Grp Pres, MedSurg & APAC
Sold $1.8M (plan status beside the amount). Exercised options and sold: 18% of the shares held or received (after tax withholding) during the period†. Stake: 37K → 77K. Why
$1.8MDisclosed plan
Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
Oct 2025: $1.3M under a disclosed planOctNov 2025: $6.2M under a disclosed planNovDec 2025: $1.8M under a disclosed planDecJanFeb 2026: $15.0M under a disclosed plan$15.0MFebMarAprMayJunJulAugSepOct

Common questions

Is the Boston Scientific CEO selling stock?

Yes. Michael Mahoney sold 161K shares ($15.0M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Boston Scientific insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any Boston Scientific insiders buying?

Yes. 5 officers or directors reported 10 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

How much of their stake did Boston Scientific insiders sell?

About 8.1% of the shares they held or received (after tax withholding) during the period. The usual measure, against starting holdings alone, can't be used here because most of the shares sold arrived during the period, through vesting or option exercises. That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold4 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan
Michael Mahoney
Chairman, President & CEO, Director
$15.0M
161K shares
7%†
Exercised options and sold. Stake: 1.68M → 1.61M
i
† Michael Mahoney exercised options and sold those shares, so this is shares sold as a share of the 1.68M held at the start plus the 786K received, less 155K withheld by the company for taxes.
Disclosed plan
Joseph Fitzgerald
EVP & Group Pres, Cardiology
$5.0M
50K shares
15%†
Exercised options and sold. Stake: 184K → 283K
i
† Joseph Fitzgerald exercised options and sold those shares, so this is shares sold as a share of the 184K held at the start plus the 199K received, less 39K withheld by the company for taxes.
Disclosed plan
Ellen Zane
Director
$2.6M
26K shares
70%Disclosed plan
Arthur Butcher
EVP& Grp Pres, MedSurg & APAC
$1.8M
17K shares
18%†
Exercised options and sold. Stake: 37K → 77K
i
† Arthur Butcher exercised options and sold those shares, so this is shares sold as a share of the 37K held at the start plus the 88K received, less 30K withheld by the company for taxes.
Disclosed plan
The full ownership picture19 of 20 insiders fully reconciled · 20 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 9, 2025SoldHeld Oct 9, 2026Still held
Michael Mahoney
Chairman, President & CEO, Director
1.68M−161K1.61Mnot meaningful
Vesting, gifts, unvested awards and holding lines for Michael Mahoney
+151Kshares vested or exercised
−375Kgifted (net of own trusts)
−155Kwithheld by the company for taxes
126K → 126Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock1,476,8821,590,024
TrustCommon Stock201,4780
401(k)Common Stock022,119

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
98,814$24.55Feb 28, 2027$2.4M
231,739$27.09Feb 15, 2028$5.1M
144,516$64.99Feb 12, 2034$0
90,915$106.14Feb 13, 2035$0
131,329$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Joseph Fitzgerald
i
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
EVP & Group Pres, Cardiology
184K−50K283Knot meaningful
Vesting, gifts, unvested awards and holding lines for Joseph Fitzgerald
+65Kshares vested or exercised
−10Kgifted (net of own trusts)
−39Kwithheld by the company for taxes
34K → 38Kunvested awards, start → end
  • Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock178,342213,907
ChildCommon Stock5,2345,234
401(k)Common Stock064,198

Additional holdings last reported Jan 1, 2023, not confirmed since: 7,428 shares. Not included in any total or percentage on this page.

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
36,509$64.99Feb 12, 2034$0
28,789$106.14Feb 13, 2035$0
43,776$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

John Sununu
Director
55K055Kno sales
Vesting, gifts, unvested awards and holding lines for John Sununu
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock54,72354,723
David Wichmann
Director
42K045Kno sales
Vesting, gifts, unvested awards and holding lines for David Wichmann
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock41,58245,382
Ellen Zane
Director
37K−26K28K75%
Vesting, gifts, unvested awards and holding lines for Ellen Zane
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock37,02527,934
Arthur Butcher
i
Minor difference of 22 shares. Difference is under 0.5% of holdings.
EVP& Grp Pres, MedSurg & APAC
37K−17K77Knot meaningful
Vesting, gifts, unvested awards and holding lines for Arthur Butcher
+30Kshares vested or exercised
0gifted (net of own trusts)
−30Kwithheld by the company for taxes
28K → 30Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock23,60056,887
401(k)Common Stock13,35520,228

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
28,396$64.99Feb 12, 2034$0
23,031$106.14Feb 13, 2035$0
35,817$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Reconciliation: minor difference of 22 shares. Difference is under 0.5% of holdings.

Jonathan Monson
i
New Form 3 filed 2025-06-30; earlier filings set aside.
EVP and CFO
35K049Kno sales
Vesting, gifts, unvested awards and holding lines for Jonathan Monson
+7.1Kshares vested or exercised
0gifted (net of own trusts)
−3.3Kwithheld by the company for taxes
26K → 30Kunvested awards, start → end
  • New Form 3 filed 2025-06-30; earlier filings set aside.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock35,28939,063
401(k)Common Stock09,908

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
12,004$27.09Feb 15, 2028$266K
14,299$37.50Feb 17, 2031$168K
8,605$40.12Feb 21, 2029$78K
10,346$42.16Feb 18, 2030$73K
10,692$42.90Jul 1, 2029$68K
13,180$44.19Feb 16, 2032$66K
15,503$45.88Aug 2, 2031$52K
12,702$47.28Feb 14, 2033$25K
10,543$56.14Dec 1, 2033$0
14,180$64.99Feb 12, 2034$0
7,165$106.14Feb 13, 2035$0
22,173$104.78Jul 1, 2035$0
27,857$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Vance Brown
EVP, GC and Corp. Secretary
33K054Kno sales
Vesting, gifts, unvested awards and holding lines for Vance Brown
+6.3Kshares vested or exercised
0gifted (net of own trusts)
−15Kwithheld by the company for taxes
14K → 16Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock33,45154,244

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
15,212$64.99Feb 12, 2034$0
11,515$106.14Feb 13, 2035$0
17,510$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

John Sorenson
EVP, Global Operations
19K019Kno sales
Vesting, gifts, unvested awards and holding lines for John Sorenson
0shares vested or exercised
0gifted (net of own trusts)
19K → 19Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock18,70518,705

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
18,254$64.99Feb 12, 2034$0
10,909$106.14Feb 13, 2035$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Edward Ludwig
Director
18K030Kno sales
Vesting, gifts, unvested awards and holding lines for Edward Ludwig
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock17,97930,359
Miriam O'Sullivan
i
Minor difference of 280 shares. Small increase from an employee stock purchase plan. Small increase from an employee stock purchase plan.
SVP, Chief HR Officer
17K019Kno sales
Vesting, gifts, unvested awards and holding lines for Miriam O'Sullivan
+3.7Kshares vested or exercised
−260gifted (net of own trusts)
−1.2Kwithheld by the company for taxes
13K → 14Kunvested awards, start → end
  • Small increase from an employee stock purchase plan. Filing
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock14,77717,302
SpouseCommon Stock1,7311,731

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,004$27.09Feb 15, 2028$44K
14,299$37.50Feb 17, 2031$168K
12,908$40.12Feb 21, 2029$117K
9,624$42.16Feb 18, 2030$68K
13,180$44.19Feb 16, 2032$66K
13,496$47.28Feb 14, 2033$26K
11,817$64.99Feb 12, 2034$0
6,061$106.14Feb 13, 2035$0
11,143$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Reconciliation: minor difference of 280 shares. Small increase from an employee stock purchase plan.

Jessica Mega
Director
8.2K012Kno sales
Vesting, gifts, unvested awards and holding lines for Jessica Mega
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock8,23512,035
Susan Morano
Director
6.6K014Kno sales
Vesting, gifts, unvested awards and holding lines for Susan Morano
0shares vested or exercised
0gifted (net of own trusts)
4K → 4Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock6,63913,784
David Habiger
Director
5.6K017Kno sales
Vesting, gifts, unvested awards and holding lines for David Habiger
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock5,62817,160
Padraig O'Connor
i
Minor difference of 264 shares. Small increase from an employee stock purchase plan. Small increase from an employee stock purchase plan. Started reporting during the period; starting holdings are from the Form 3.
EVP, Global Operations
3.9K07.9Kno sales
Vesting, gifts, unvested awards and holding lines for Padraig O'Connor
+6.6Kshares vested or exercised
0gifted (net of own trusts)
−2.9Kwithheld by the company for taxes
15K → 13Kunvested awards, start → end
  • Small increase from an employee stock purchase plan. Filing
  • Started reporting during the period; starting holdings are from the Form 3.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock3,8857,892

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
13,822$37.50Feb 17, 2031$162K
12,050$44.19Feb 16, 2032$61K
14,290$47.28Feb 14, 2033$28K
12,998$64.99Feb 12, 2034$0
5,151$106.14Feb 13, 2035$0
11,939$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Reconciliation: minor difference of 264 shares. Small increase from an employee stock purchase plan.

Yoshiaki Fujimori
Director
2.1K02.1Kno sales
Vesting, gifts, unvested awards and holding lines for Yoshiaki Fujimori
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock2,0812,081
Emily Woodworth
!
Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +280 shares on Feb 12, 2026 (Direct). See the filing Sales and other transactions for Emily Woodworth are complete.
SVP, Global Controller and CAO
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Emily Woodworth
+4Kshares vested or exercised
0gifted (net of own trusts)
−1.9Kwithheld by the company for taxes
12K → 14Kunvested awards, start → end

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +280 shares on Feb 12, 2026 (Direct). The balances below are as reported, not verified totals.

Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock4323,123
401(k)Common Stock02,930

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,383$37.50Feb 17, 2031$28K
4,237$44.19Feb 16, 2032$21K
5,955$47.28Feb 14, 2033$12K
5,908$64.99Feb 12, 2034$0
3,421$67.13Mar 1, 2034$0
5,732$106.14Feb 13, 2035$0
5,584$74.12Feb 12, 2036$0

Estimate: options held × ($49.22 − strike price), using the most recent insider trade price on Form 4 (Aug 25, 2026), not a market close.

Cathy Smith
i
Started reporting during the period; starting holdings are from the Form 3.
Director
1410141no sales
Vesting, gifts, unvested awards and holding lines for Cathy Smith
0shares vested or exercised
0gifted (net of own trusts)
0 → 6.9Kunvested awards, start → end
  • Started reporting during the period; starting holdings are from the Form 3.
Held throughShare classOct 9, 2025Oct 9, 2026
TrustCommon Stock141141
Cheryl Pegus
Director
001.8Kno sales
Vesting, gifts, unvested awards and holding lines for Cheryl Pegus
0shares vested or exercised
0gifted (net of own trusts)
5.9K → 11Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock01,770
Christophe Weber
Director
003.8Kno sales
Vesting, gifts, unvested awards and holding lines for Christophe Weber
0shares vested or exercised
0gifted (net of own trusts)
0 → 2.7Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock03,786

19 of 20 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (16 exactly, 3 with a minor or footnoted difference). For 1 we show sales but not holdings; the ! icon on that row explains why. Percentages cover 17 of 20 officers and directors. Left out: Emily Woodworth (holdings couldn't be fully reconciled); Cheryl Pegus and Christophe Weber (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$24.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $24.3M across 253,996 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Taxes

247,585 shares ($18.4M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 5 buyers (10 trades)

5 officers and directors bought shares in this period, in 10 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 18 purchase trades.

SellerShares soldProceedsUnder a disclosed planShare of totalSales dates
Michael Mahoney
Chairman, President & CEO, Director
161K$15.0M100%62%Feb 2, 2026 to Feb 2, 2026
Joseph Fitzgerald
EVP & Group Pres, Cardiology
50K$5.0M100%20%Nov 3, 2025 to Nov 3, 2025
Ellen Zane
Director
26K$2.6M100%11%Oct 27, 2025 to Nov 6, 2025
Arthur Butcher
EVP& Grp Pres, MedSurg & APAC
17K$1.8M100%7%Dec 1, 2025 to Dec 1, 2025

Sales by month

MonthSale proceedsDisclosed planTo cover taxesNo plan disclosed
Oct 2025$1.3M$1.3M$0$0
Nov 2025$6.2M$6.2M$0$0
Dec 2025$1.8M$1.8M$0$0
Jan 2026$0$0$0$0
Feb 2026$15.0M$15.0M$0$0
Mar 2026$0$0$0$0
Apr 2026$0$0$0$0
May 2026$0$0$0$0
Jun 2026$0$0$0$0
Jul 2026$0$0$0$0
Aug 2026$0$0$0$0
Sep 2026$0$0$0$0
Oct 2026$0$0$0$0
Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about one-fifth of the 5-year average. 4 insiders sold; the average is 12 a year.

12 months endingShares soldInsiders who soldProceeds
Oct 9, 2026
Latest 12 months
254K4$24.3M
Oct 9, 2025
1 year earlier
1.27M12$127M
Oct 9, 2024
2 years earlier
1.17M11$85.7M
Oct 10, 2023
3 years earlier
1.04M12$51.0M
Oct 10, 2022
4 years earlier
910K12$37.9M
Oct 10, 2021
5 years earlier
1.76M15$73.6M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty1 insider whose holdings couldn't be fully reconciled

Emily Woodworth: holdings couldn't be fully reconciled (difference of 544 shares). Balance changed without a matching transaction, and the footnote does not state the amount: +280 shares on Feb 12, 2026 (Direct). Filing, Feb 12, 2026

Footnote: "Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. | Includes shares acquired on June 30, 2025 under the Company's Employee Stock Purchase Plan based upon the most current data available."

Arthur Butcher: minor difference of 22 shares. Difference is under 0.5% of holdings.

Miriam O'Sullivan: minor difference of 280 shares. Small increase from an employee stock purchase plan.

Padraig O'Connor: minor difference of 264 shares. Small increase from an employee stock purchase plan.

Inferred rename: "401(k) Plan" is treated as the same holder as "401(k)", because the old name was never reported again and the new one opened with the same balance (5,506 shares). Old name, new name

Inferred rename: "Trust" is treated as the same holder as "Trust 2", because the old name was never reported again and the new one opened with the same balance (0 shares). Old name, new name

Inferred typo: the share class "Commmon Stock" is treated as the same class as "Common Stock" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Lawrence Best, 5,506 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology3,510 filings from SEC EDGAR, and how we read them

All 3,510 Forms 3, 4 and 5 filed for Boston Scientific (SEC CIK 885725) from Sep 20, 2002 to Sep 3, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 78 filings were left out because Boston Scientific filed them as an owner of another company's stock. 67 older filings exist only on paper and could not be read.

Probable 2-for-1 stock split on or before Nov 5, 2003 (split date stated in a footnote). Splits aren't reported as transactions; 5 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (71)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Jeffrey MirvissFeb 25, 202550,766 shares, last reported balance as of Feb 25, 2025
Daniel BrennanFeb 19, 2025225,808 shares, last reported balance as of Feb 19, 2025
Wendy CarruthersDec 4, 202429,308 shares, last reported balance as of Dec 2, 2024
Eric ThepautMay 13, 202431,422 shares, last reported balance as of May 10, 2024
Charles DockendorffMay 13, 202490,202 shares, last reported balance as of May 9, 2024
Nelda ConnorsMay 5, 202336,069 shares, last reported balance as of May 4, 2023
David RouxMay 5, 202373,591 shares, last reported balance as of May 4, 2023
Donna JamesMay 6, 202221,879 shares, last reported balance as of May 10, 2018
Meghan ScanlonMay 2, 202224,461 shares, last reported balance as of May 1, 2022
Jodi EddyApr 4, 202223,263 shares, last reported balance as of Apr 1, 2022
Scott OlsonApr 1, 202214,518 shares, last reported balance as of Apr 1, 2022
Ian MeredithMar 29, 202228,082 shares, last reported balance as of Mar 28, 2022
Maulik NanavatyMar 2, 2022177,258 shares, last reported balance as of Feb 28, 2022
David PierceMar 2, 2022No balance on record
Edward MackeyMar 2, 202252,944 shares, last reported balance as of Feb 28, 2022
Desiree Ralls-MorrisonFeb 23, 202129,909 shares, last reported balance as of Feb 21, 2021
Stephen MacmillanOct 5, 20208,000 shares, last reported balance as of Oct 1, 2020
Kevin BallingerMar 5, 202080,085 shares, last reported balance as of Mar 4, 2020
Xin WangFeb 18, 202078,985 shares, last reported balance as of Feb 15, 2020
Michael PhalenMar 1, 2018135,793 shares, last reported balance as of Feb 28, 2018
Timothy PrattDec 4, 2017154,681 shares, last reported balance as of Dec 1, 2017
Supratim BoseOct 5, 2017320,301 shares, last reported balance as of Oct 4, 2017
Keith DawkinsMar 2, 201768,165 shares, last reported balance as of Feb 28, 2017
Kristina JohnsonMay 4, 20168,494 shares, last reported balance as of May 3, 2016
Nj Nicholas Jr.Apr 5, 2016755,047 shares, last reported balance as of Aug 19, 2014
Peter NicholasApr 5, 201616,337,562 shares, last reported balance as of Apr 1, 2016
Karen PrangeMar 8, 201639,395 shares, last reported balance as of Mar 8, 2016
Ernest MarioNov 17, 2015136,032 shares, last reported balance as of Nov 16, 2015
John AbeleAug 24, 20151,344,081 shares, last reported balance as of Aug 21, 2015
Jean LanceFeb 18, 2015125,690 shares, last reported balance as of Feb 16, 2015
John OnuscheckJan 2, 2015116,025 shares, last reported balance as of Jan 1, 2015
Uwe ReinhardtNov 3, 2014164,379 shares, last reported balance as of Oct 31, 2014
Bruce ByrnesNov 3, 2014112,097 shares, last reported balance as of Oct 31, 2014
Kenneth PucelMar 4, 2014128,517 shares, last reported balance as of Feb 28, 2014
Jeffrey CapelloDec 2, 2013447 shares, last reported balance as of Nov 27, 2013
Katharine BartlettMay 8, 201352,464 shares, last reported balance as of May 7, 2013
Otha Spriggs IIISep 11, 201212,738 shares, last reported balance as of Sep 7, 2012
William KuchemanAug 2, 2012180,828 shares, last reported balance as of Jul 31, 2012
Lawrence NeumannMay 14, 201277,879 shares, last reported balance as of May 10, 2012
Brian BurnsMar 1, 201284,188 shares, last reported balance as of Feb 28, 2012
John ElliottFeb 29, 2012603,676 shares, last reported balance as of Dec 31, 2011
John PedersenFeb 21, 201218,290 shares, last reported balance as of Feb 16, 2012
Stephen MoreciJul 6, 201144,579 shares, last reported balance as of Jul 1, 2011
Sam LenoJun 8, 2011432,240 shares, last reported balance as of Jun 6, 2011
Ray GrovesApr 4, 201137,167 shares, last reported balance as of Oct 30, 2008
Andrew MilaniFeb 14, 2011No balance on record
Marye FoxMay 13, 201021,815 shares, last reported balance as of May 5, 2009
Fred ColenMay 12, 201073,404 shares, last reported balance as of May 10, 2010
John PepperApr 2, 201061,800 shares, last reported balance as of May 11, 2009
James GilbertMar 2, 201067,613 shares, last reported balance as of Feb 24, 2010
Donovan PaulFeb 17, 201033,103 shares, last reported balance as of Feb 12, 2010
David McFaulFeb 17, 201047,375 shares, last reported balance as of Feb 12, 2010
William McConnell Jr.Jul 28, 200988,082 shares, last reported balance as of Jul 24, 2009
Donald BaimJul 14, 200953,788 shares, last reported balance as of Jul 10, 2009
Lucia QuinnJul 2, 200949,809 shares, last reported balance as of Jul 1, 2009
Ursula BurnsMay 7, 200932,001 shares, last reported balance as of May 5, 2009
Warren RudmanMay 7, 2009No balance on record
James TobinFeb 26, 2009566,550 shares, last reported balance as of Oct 9, 2008
Paul LavioletteJul 3, 200879,631 shares, last reported balance as of Jul 1, 2008
Joel FleishmanMay 8, 2008125,691 shares, last reported balance as of May 6, 2008
Nancy DeparleMay 8, 200813,886 shares, last reported balance as of May 6, 2008
Joel FleishmanMay 8, 200818,250 shares, last reported balance as of May 6, 2008
Paul SandmanMar 14, 200869,746 shares, last reported balance as of Feb 29, 2008
PROMERICA LPAug 9, 200754,635,185 shares, last reported balance as of Aug 7, 2007
Lawrence BestJul 17, 2007318,069 shares, last reported balance as of Jul 6, 2007
Jeffrey GoodmanJul 5, 200710,460 shares, last reported balance as of Jul 1, 2007
Mark BartellMay 30, 200752,431 shares, last reported balance as of May 25, 2007
Mary RussellJan 5, 20064,706 shares, last reported balance as of Jan 3, 2006
Dennis OcwiejaMay 12, 2005No balance on record
Robert MacleanFeb 14, 200531,957 shares, last reported balance as of Dec 21, 2004
James Taylor Jr.Feb 10, 200520,167 shares, last reported balance as of Feb 9, 2005

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.